Pharma

Your Article Summary

See Latest Articles

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
Forest Laboratories, 06/22/09

Forest Laboratories, Inc. announced positive results from two global multi-center Phase III studies of ceftaroline for the treatment of community-acquired bacterial pneumonia. The top-line data in each of the pivotal trials demonstrate that ceftaroline met the primary objective of non-inferiority and achieved high clinical cure rates compared with ceftriaxone in patients with moderate to severe community-acquired bacterial pneumonia requiring hospitalization.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Short-term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin-resistant Staphylococcus aureus infection in elective colon cancer surgery: Results of a prospective randomized trial
Surgery Today, 12/14/09

Roche, Genentech and Biogen Idec announce positive results from first phase III trial of ocrelizumab in rheumatoid arthritis
Roche, 12/14/09

Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease
Clinical Drug Investigation, 12/14/09

 See all of Drug Trials